- Egypt’s Reme-D Raises $1.45 Million in Pre-Series A Funding to Expand Molecular Diagnostics
- Round led by Anara Impact Capital, with participation from Global Innovation Fund, Africa Health Ventures, and other investors to support advanced diagnostic technologies for infectious diseases and hepatitis
Egyptian healthtech company Reme-D, which develops and manufactures molecular diagnostic solutions, has closed a $1.45 million Pre-Series A funding round led by Anara Impact Capital, with participation from Global Innovation Fund, Africa Health Ventures, and other investors.
About Reme-D
Founded to improve access to advanced diagnostics across Africa and underserved markets, Reme-D develops accurate, rapid, affordable, and temperature-resilient molecular diagnostic tests for diseases including tuberculosis (TB), HIV, hepatitis, and human papillomavirus (HPV), a leading cause of cervical cancer in women.
Funding Details
The new funding will support the company’s plans to expand its manufacturing capacity, strengthen its regional footprint, and broaden its product portfolio.
Reme-D also plans to introduce new diagnostic tests covering genetic disorders and cancer, while increasing the number of temperature-resilient tests that can be easily transported and stored in remote areas and healthcare facilities with limited infrastructure.
Since 2023, the company has developed and commercialized 30 diagnostic products from its manufacturing facility in Cairo.
It has supplied more than 550,000 diagnostic tests across Egypt, Kenya, and Sudan.
Reme-D serves public and private laboratories, hospitals, and research institutions, while its products have been featured in international scientific publications. The company has also filed a U.S. patent application for its proprietary technology.
Reme-D recently equipped a solar-powered mobile laboratory, specially commissioned by the World Health Organization (WHO) Egypt Office, to support the Egyptian Ministry of Health’s efforts in monitoring vector-borne diseases in remote areas.
After growing its team from five to 50 employees, the company is preparing to relocate to a 1,500-square-meter facility and upgrade its manufacturing equipment, increasing production capacity tenfold.
It also plans to continue expanding across African markets while strengthening its quality assurance and regulatory capabilities.
Salma Tammam, Founder and CEO of Reme-D, said:
“Success, for us, means that patients across Africa and the Global South are no longer prevented from accessing life-saving disease diagnosis because of cost or the lack of advanced molecular testing. That is our ultimate goal.”
She added:
“We are particularly proud to showcase what African science and African women can contribute to the global business community”.
She Said:
” We are grateful to have the support of a remarkable group of investors who share our vision of creating meaningful, real-world impact.”
Mohamed Hussain, Principal at Anara Impact Capital, said:
“We were impressed by Salma and the Reme-D team’s ability to combine deep scientific expertise with a practical understanding of the challenges involved in delivering diagnostics to underserved markets”.
He added:
” Reme-D has already demonstrated that high-quality molecular diagnostics can be developed and manufactured locally, and we are excited to support the company as it scales its impact across the Middle East, Africa, and beyond.”
Read the article in
